companydata.dkcompanydata.dk

Ascendis Pharma Oncology Division A/S: Financial statements 2025

CVR: 41034076

Source: annual report 2025, Danish Business Authority

01/01/2025 – 31/12/2025

Ascendis Pharma Oncology Division A/S (CVR 41034076) has filed annual accounts for 2025. In 2025, the company reported a gross profit of EUR -85,226,000 and a net result of EUR -110,131,000 compared with EUR -106,375,000 the year before. Equity in the 2025 report amounted to EUR -501,637,000.

Gross Profit
EUR -85,226,000
Profit/Loss
EUR -110,131,000
Equity
EUR -501,637,000
Employees
0

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025--85.2M EUR-110.1M EUR-501.6M EUR0
2024--92.5M EUR-106.4M EUR-391.5M EUR0
2023--140.1M EUR-144.1M EUR-285.1M EUR0
2022--62.4M EUR-64.9M EUR-141M EUR0
2021--46.7M EUR-48M EUR-76.1M EUR0

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Ascendis Pharma Oncology Division A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2025

Ascendis Pharma Oncology Division A/S: The 2024 annual report is outMay 6, 2025

Ascendis Pharma Oncology Division A/S has published its annual report for 2024. Gross profit came to DKK -92,475,000, and the net result was DKK -106,375,000.

About Ascendis Pharma Oncology Division A/S

Ascendis Pharma Oncology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -85,226,000 and a net result of EUR -110,131,000 compared with EUR -106,375,000 the year before. Equity in the 2025 report amounted to EUR -501,637,000.

Source: annual report 2025, Danish Business Authority

Other financial years